Its AastromReplicell System is a patented, integrated system of instrumentation and single-use consumable kits for the production of patient-specific cells.
AastromReplicell System is the company’s core technology for its Prescription Cell Products (PCP) business and its Cell Production Products (CPP) business.
The PCP pipeline focuses on Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells.
Aastrom is developing TRCs for the treatment of severe bone fractures, ischemic vascular disease, jaw reconstruction, and spine fusion with Phase I/II level clinical trials active in the U.
S. and EU for some of the indications.
The CPP business markets the AastromReplicell System to researchers and companies for their production of cells for clinical trials.
The company was incorporated in 1989 and is headquartered in Ann Arbor, Michigan.